NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Sigilon will receive $14.92 in cash, plus one non-tradeable contingent value right that entitles the holder to receive up to an additional $111.64 per share, for each share of Sigilon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-sgtx/ to learn more.
Please note that the merger is structured as a tender offer, such that time may be of the essence.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Contacts
Kahn Swick & Foti, LLC
Lewis S. Kahn
Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857